US2023285451A1PendingUtilityA1

Compositions and methods for treating or preventing diseases associated with oxidative stress

Assignee: CXL OPHTHALMICS LLCPriority: Mar 29, 2012Filed: Nov 14, 2022Published: Sep 14, 2023
Est. expiryMar 29, 2032(~5.7 yrs left)· nominal 20-yr term from priority
A61K 33/18A61K 9/08A61K 9/0014A61K 38/44A61L 26/0066A61L 2300/106A61L 2300/254A61K 9/0048C12Y 111/01006A61K 31/525A61P 17/00A61P 17/14A61P 27/02
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A stable pharmaceutical composition for use in corneal collagen cross-linking, comprising (a) between about 0.015% to about 5% sodium iodide by weight, (b) 0.5. % riboflavin by weight, or salts thereof, and (c) a pharmaceutically-acceptable excipient appropriate for ocular administration, wherein the pharmaceutical composition maintains a basic pH that permits iodide ion to catalytically break hydrogen peroxide into water and oxygen.

Join the waitlist — get patent alerts

Track US2023285451A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.